New antibody aimed at ARDS shows promise in early trial
NCT ID NCT05938036
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a single dose of an antibody called ALT-100 in people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial involves 15 hospitalized adults and compares the drug to a placebo. The main goal is to check safety, and researchers will also see if it helps patients breathe better and leave the hospital sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ALT-100 monoclonal antibody
What this could lead to
If successful, this could point toward a new treatment for acute respiratory distress syndrome (ARDS) that reduces time on a ventilator and shortens hospital stays.
What could go wrong
This is a very early Phase 2a trial with only 15 participants, so results may not apply to all ARDS patients. The drug may not improve outcomes or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner University of Arizona
Tucson, Arizona, 85721, United States